2018
DOI: 10.1101/432500
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Guiding dose selection of monoclonal antibodies using a new parameter (AFTIR) for characterizing ligand binding systems

Abstract: Guiding the dose selection for monoclonal antibody oncology drugs is often done using methods for predicting the receptor occupancy of the drug in the tumor. In this manuscript, previous work on characterizing target inhibition at steady state using the AFIR metric [1] is extended to include a "target-tissue" compartment and the shedding of membrane-bound targets. A new potency metric AFTIR (Averarge Free Tissue target to Initial target ratio at steady state) is derived, and it depends on only four key quantit… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2020
2020
2020
2020

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 23 publications
0
1
0
Order By: Relevance
“…From a high-level perspective, PSP involves integrating and quantitatively linking all types of information, methodologies and tools associated with the development of mechanistic models of biological/physiological processes, and pharmacology that can help in our understanding and prediction of drug response in patients. The value of MID3 approaches in decision-making is evidenced by the large number of related publications, recent examples of which can be found in [2][3][4][5]. In these examples, the reliability and explanatory power of the models depend predominantly on the level of detail included and the assumptions on which they are based.…”
Section: Mathematical Modeling and Simulation In Drug Development And Patient Managementmentioning
confidence: 99%
“…From a high-level perspective, PSP involves integrating and quantitatively linking all types of information, methodologies and tools associated with the development of mechanistic models of biological/physiological processes, and pharmacology that can help in our understanding and prediction of drug response in patients. The value of MID3 approaches in decision-making is evidenced by the large number of related publications, recent examples of which can be found in [2][3][4][5]. In these examples, the reliability and explanatory power of the models depend predominantly on the level of detail included and the assumptions on which they are based.…”
Section: Mathematical Modeling and Simulation In Drug Development And Patient Managementmentioning
confidence: 99%